Post-transplant lymphoproliferative disorders following solid-organ transplantation

Anne H Blaes, Vicki A Morrison

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


A post-transplant lymphoproliferative disorder (PTLD) is an uncommon but serious complication following solid-organ transplantation. The incidence varies, depending on the type of organ transplanted, the degree of immunosuppression, the number of episodes of acute rejection and a patients immune status to Epstein-Barr virus. The incidence of PTLD is thought to be bimodal; cases in the first year after solid-organ transplantation are typically related to Epstein-Barr virus. A second incidence occurs more than 1 year following transplantation and is typically not related to Epstein-Barr virus. A variety of therapeutic approaches has been used for these patients, with more recent strategies including the use of rituximab, with or without combination chemotherapy. Efforts continue to be made to improve the outcome of patients with PTLD.

Original languageEnglish (US)
Pages (from-to)35-44
Number of pages10
JournalExpert Review of Hematology
Issue number1
StatePublished - Mar 8 2010


  • Immunosuppression
  • Lymphoma
  • Non-Hodgkin lymphoma
  • Post-transplant lymphoproliferative disorder
  • Solid-organ transplantation


Dive into the research topics of 'Post-transplant lymphoproliferative disorders following solid-organ transplantation'. Together they form a unique fingerprint.

Cite this